The activation of the NF-kB signaling pathway in ABC DLBCL is frequently due to oncogenic mutations of CARD11 or CD79, strictly associated with canonical NF-κB and BCR activity, or both [13,14]. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.